$200m MkCap / 30c, page-17

it wasn't the nuance or the complexity that I found hilarious in your absolute desire to post in this thread....

there is no catalyst in the medium term is true with respect to trials, but I suspect there could be significant corporate actions on the table at the moment (favourable or unfavourable), and we are still in the dark about how they will proceed going forward (corporate actions aside).

The downside is not as valuable now as it was pre FDA feedback (hint, downside is limited but upside is technically unlimited, and 40 cents downside is not as valuable as $1+ downside), and with uncertainty going forward, I wouldn't expect any major Shorting at least relative to where the activity was previously.

So I wouldn't be too excited or quick to use colorful down ramping language like "catching the falling knife" just yet IMO, although the stock and the investors are currently very vulnerable (hence these threads are popping up? nah its all fair discourse im sure!).